Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib

Clin Res Cardiol. 2007 Nov;96(11):829-30. doi: 10.1007/s00392-007-0567-z. Epub 2007 Aug 21.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Renal Cell / drug therapy
  • Cardiomyopathies / chemically induced*
  • Contraindications
  • Echocardiography
  • Female
  • Humans
  • Indoles / adverse effects*
  • Kidney Neoplasms / drug therapy
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrroles / adverse effects*
  • Severity of Illness Index
  • Sunitinib
  • Ventricular Dysfunction, Left / chemically induced*

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Protein-Tyrosine Kinases
  • Sunitinib